|
Sign In to gain access to subscriptions and/or personal tools.
|
Delayed thrombin generation is not associated with fibrinopeptide formation during prolonged cardiopulmonary bypass with hirudin anticoagulation
D Belway
Department of Cardiovascular Perfusion, University of Ottawa Heart Institute, Ottawa, Canada
F D Rubens
Department of Surgery, Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Canada
B Henley
A Babaev
Department of Cardiovascular Perfusion, University of Ottawa Heart Institute, Ottawa, Canada
T Mesana
Department of Surgery, Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Canada
Patients with heparin-induced thrombocytopenia urgently requiring surgery with cardiopulmonary bypass (CPB) present a unique management challenge that must be addressed by the use of alternative anticoagulants. Although clinical success with the direct thrombin inhibitor hirudin has been reported, there is sparse information in the literature supporting the efficacy of this drug as an anti-thrombotic to prevent fibrin formation during CPB. In this report, we describe the efficacy of this drug to prevent thrombin-mediated fibrin formation during CPB.
References
- Rubens FD, Lavalee G, Ruel MA, Mesana T, Bourke M. Delayed thrombin generation with hirudin anticoagulation during prolonged cardiopulmonary bypass . Ann Thorac Surg 2005; 79: 334336 .[Abstract/Free Full Text]
- Koster A, Kuppe H, Hetzer R, Sodian R, Crystal GJ, Mertzlufft F. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin . Anesthesiology 1998; 89: 777780 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kappa JR, Fisher CA, Todd B et al. Intraoperative management of patients with heparin-induced thrombocytopenia . Ann Thorac Surg 1990; 49: 714722 .[Abstract]
- Koster A, Loebe M, Hansen R et al. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the ACT II device . J Thorac Cardiovasc Surg 2000; 199: 12781283 .
- Rao AK, Sun L, Chesebro JH et al. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial . Circulation 1996; 94: 23892395 .[Abstract/Free Full Text]
- Edmunds HL, Hessel EA, Colman RW, Menasche P. Extracorporeal circulation. In Edmunds HL, Cohn LH eds. Cardiac surgery in the adult. McGraw-Hill Professional , 2003: 315387.
- Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors . J Clin Invest 1990; 86: 385391 .[Web of Science][Medline]
[Order article via Infotrieve]
- Markwardt F. Hirudin and derivatives as anticoagulant agents . Thromb Hemostas 1991; 66: 141152 .[Web of Science][Medline]
[Order article via Infotrieve]
- Fenton JW, Villanueva GB, Ofosu FA, Maraganore JM. Thrombin inhibition by hirudin: how hirudin inhibits thrombin . Haemostasis 1991; 21: 2731 .[Web of Science][Medline]
[Order article via Infotrieve]
- Zoldhelyi P, Bichler J, Owen WG et al. Coronary heart disease/myocardial infarction: persistent thrombin generation in humans during specific thrombin inhibition with hirudin . Circulation 1994; 90: 26712678 .[Abstract/Free Full Text]
- Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin . Biochem J 1986; 25: 46224628 .
Perfusion, Vol. 21, No. 5,
259-262 (2006)
DOI: 10.1177/0267659106074768

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|